Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by LSV Asset Management

Key Points

• LSV Asset Management reduced its stake in Lantheus Holdings, Inc. by 21.1%, now holding 370,600 shares worth approximately $36.17 million.
• Several other institutional investors, including Norges Bank and Pictet Asset Management, have made significant adjustments to their holdings in Lantheus during the last quarter.
• Lantheus's recent earnings report showed a quarterly EPS of $1.53, missing analysts' expectations, with revenue of $372.76 million, reflecting a year-over-year increase of only 0.8%.

LSV Asset Management lessened its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 21.1% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 370,600 shares of the medical equipment provider's stock after selling 99,100 shares during the quarter. LSV Asset Management owned 0.54% of Lantheus worth $36,171,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in LNTH. Janus Henderson Group PLC boosted its position in Lantheus by 72.7% during the fourth quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock worth $554,583,000 after purchasing an additional 2,610,118 shares in the last quarter. Farallon Capital Management LLC increased its holdings in shares of Lantheus by 79.9% in the fourth quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock valued at $475,590,000 after purchasing an additional 2,361,000 shares during the last quarter. T. Rowe Price Investment Management Inc. increased its holdings in shares of Lantheus by 40.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock valued at $135,025,000 after purchasing an additional 435,445 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Lantheus by 2.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,347,082 shares of the medical equipment provider's stock valued at $120,510,000 after purchasing an additional 30,891 shares during the last quarter. Finally, Silvercrest Asset Management Group LLC increased its stake in Lantheus by 39.1% during the fourth quarter. Silvercrest Asset Management Group LLC now owns 973,888 shares of the medical equipment provider's stock worth $87,124,000 after acquiring an additional 273,838 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company's stock.

Analyst Ratings Changes

LNTH has been the subject of a number of recent analyst reports. Truist Financial cut their price objective on Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a research report on Thursday, May 8th. William Blair reiterated a "market perform" rating on shares of Lantheus in a research note on Wednesday, July 16th. Mizuho lowered their price objective on Lantheus from $120.00 to $70.00 and set an "outperform" rating for the company in a research report on Thursday. JMP Securities lowered their price objective on Lantheus from $112.00 to $73.00 and set a "market outperform" rating for the company in a research report on Thursday. Finally, Wall Street Zen upgraded Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, Lantheus presently has a consensus rating of "Moderate Buy" and an average target price of $114.50.

Lantheus Stock Performance

LNTH traded up $2.99 on Thursday, hitting $54.86. 3,899,545 shares of the company traded hands, compared to its average volume of 1,120,053. The company has a 50 day moving average of $77.09 and a 200-day moving average of $87.42. Lantheus Holdings, Inc. has a 12-month low of $47.25 and a 12-month high of $118.21. The stock has a market capitalization of $3.80 billion, a PE ratio of 15.59 and a beta of 0.14. The company has a quick ratio of 5.46, a current ratio of 5.74 and a debt-to-equity ratio of 0.49.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a net margin of 16.55% and a return on equity of 36.99%. The firm had revenue of $372.76 million during the quarter, compared to analysts' expectations of $377.37 million. During the same period in the previous year, the business earned $1.69 earnings per share. The business's revenue for the quarter was up .8% on a year-over-year basis. Sell-side analysts anticipate that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Insider Activity

In other news, Director Mary Anne Heino sold 26,066 shares of the company's stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total value of $2,002,650.78. Following the sale, the director directly owned 318,650 shares in the company, valued at $24,481,879.50. This represents a 7.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.50% of the stock is owned by corporate insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.